For patient-related information about the ICT-107 cancer vaccine phase II program please:

  1. Access the ICT-107 FAQ (Frequently Asked Questions) click here.
  2. Send an email message to clintrials@imuc.com, including your contact information and your specific questions.
  3. Call 818 264 2315 and leave a brief message, including your contact information and questions.

Someone knowledgeable about the ICT-107 clinical program will respond to your inquiry shortly.

PRESS RELEASES

Friday, November 14, 2014
ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data at the Society for Neuro-Oncolo read more ...
Monday, November 10, 2014
ImmunoCellular Therapeutics Announces Third Quarter 2014 Financial Results read more ...
Friday, September 26, 2014
ImmunoCellular Therapeutics to Present at Livingston Securities Conference on October 1, 2014 read more ...
Wednesday, September 24, 2014
ImmunoCellular Therapeutics Expands Cancer Immunotherapy Platform with Antigen-Specific T-cell Tech read more ...
Wednesday, September 17, 2014
ImmunoCellular Therapeutics Receives Positive Regulatory Feedback on ICT-107 Supporting Advancement read more ...

EVENTS

Friday, November 14, 2014
ImmunoCellular to Host Conference Call on Tuesday, November 18th
Friday, September 26, 2014
ImmunoCellular Therapeutics October 1, 2014 Livingston Securities presentation webcast
 
Copyright 2014 by Immunocellular Therapeutics, Ltd.
All Rights Reserved